Services Database Covid Medicine Delivery Unit (CMDU)

Service Aims and Intended Outcomes

3.1 The provider will maintain an agreed stock of medicines used in the treatment of covid-19, intended for supply by the community pharmacy against FP10 prescriptions.
3.2 Maintaining stock of medicines used in the treatment of covid-19 will ensure the public has access to these medicines during both normal working hours, and evenings and weekends, where the pharmacy is open. The stock list may be subject to changes in line with national or local guidance.
3.3 The Provider will, in their best endeavours, dispense prescriptions presented for covid-19 medicines within one hour of receipt.
3.4 The Provider will support patients, carers, and clinicians by providing them with up-to-date information and advice, with referral to specialist services where appropriate.
3.5 To participate in the development and provision of a local pathway ensuring routine access to COVID-19 oral medication treatment for individuals at highest risk of hospitalisation.
3.6 To act as a point of contact for patients during their course of treatment in line with core contractual requirements around provision of advice and support for prescribed medicines and liaise with local services as deemed appropriate.
3.7 Approach to health inequalities – local pathway to ensure equitable access to services.
3.8 Data and reporting requirements – ensure effective monitoring and data sharing to support service improvement and commissioning of service after pilot.
3.9 Where requested, the pharmacist will provide advice to the healthcare professional regarding the prescribing or dosage that should be administered to the patient.
3.10 The Provider will accept patient’s medicine returns for destruction from patients, carers, or other healthcare professionals as per the NHS Community Pharmacy Contract: Essential Services Disposal of Unwanted Medicines.

5.1. The Provider shall ensure that pharmacists and staff involved in the provision of the service are appropriately trained, are aware of and operate within national and regional guidelines outlined below.
5.2. Providers are required to:
5.3. Watch a recording of a locally delivered clinical webinar which will be confirmed to all participating community pharmacies by emails. This is a maximum of 1.5 hours in duration.
5.4. Familiarise themselves with NICE TA 878 https://www.nice.org.uk/guidance/ta878 and NICE Guideline NG191: 4 Therapeutics for COVID-19 | COVID-19 rapid guideline: managing COVID-19 | Guidance | NICE
5.5. Familiarise themselves with the SPC for nirmatrelvir plus ritonavir (Paxlovid) and molnupiravir (Lagevrio) https://www.medicines.org.uk/emc/product/13145 https://www.medicines.org.uk/emc/product/13044
5.6. Familiarise themselves with the Liverpool COVID 19 drug interaction checker Liverpool COVID-19 Interactions (covid19-druginteractions.org))